RAGE antagonist peptide (TFA)

RAGE antagonist peptide TFA is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide TFA prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide TFA possesses anti-tumor and anti-inflammatory activities[1][2].

Product Specifications

UNSPSC

12352209

Target

Amyloid-β

Type

Peptides

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/rage-antagonist-peptide-tfa.html

Purity

99.41

Solubility

DMSO : ≥ 50 mg/mL|H2O : 14.29 mg/mL (ultrasonic)

Smiles

O=C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCSC)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(C)C)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCC(O)=O)NC(C)=O.O=C(O)C(F)(F)F

Molecular Formula

C59H102F3N13O19S

Molecular Weight

1386.58

References & Citations

[1]Thiruvengadam Arumugam, et al. S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin Cancer Res. 2012 Aug 15;18 (16) :4356-64.|[2]Lihong Yao, et al. The receptor for advanced glycation end products is required for β-catenin stabilization in a chemical-induced asthma model. Br J Pharmacol. 2016 Sep;173 (17) :2600-13.

Shipping Conditions

Blue Ice

Storage Conditions

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

Scientific Category

Peptides

Clinical Information

No Development Reported

Citation 01

Int J Biol Sci. 2024 Jan 1;20 (2) :784-800.|Adv Biol (Weinh) . 2025 Jun 4:e00761.|Cell Commun Signal. 2023 May 1;21 (1) :86.|J Immunol. 2025 Jun 28:vkaf125.